Emerging technologies focused on
Improving Patient Outcomes
for cost effective healthcare
Emerging technologies focused on
Improving Patient Outcomes
for cost effective healthcare
Images produced from new medical technologies that incorporate PET (positron emission tomography) are similar to a weather map you see on your local news.
Our patented imaging agent binds to a receptor (called VPAC1) on the surface of many cancer cells. We are utilizing this technology to create a urine screen to detect prostate/bladder cancer and an imaging agent to transform the diagnosis of breast and prostate cancer.
Our patented imaging agent directly visualizes the cellular proliferation of a tumor. We are developing this product to rapidly assess an individual’s response to cancer therapy.
David W. Townsend receives SNMMI 2015 Aebersold Award for Nuclear Medicine Achievement
NuView, Otsuka Team up to Develop, Commercialize Biomarker for Breast, Prostate Cancer: GenomeWeb
NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal: FierceDiagnostics
NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical
Healthcare Imaging Pioneer and Humanitarian Joins NuView Life Sciences Board
Dr. Nancy Snyderman: What’s Your Mammogram Risk?
Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
We welcome inquiries with interested individuals, media and potential investors. Please drop us a note in the contact form or call us directly.